MedPath

OncoVerity, Inc.

🇺🇸United States
Ownership
Holding
Established
2022-01-01
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:6
Completed:3

Trial Phases

2 Phases

Phase 1:7
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (70.0%)
Phase 2
3 (30.0%)

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Phase 2
Recruiting
Conditions
Acute myeloid leukemia
First Posted Date
2024-07-19
Last Posted Date
2025-03-21
Lead Sponsor
Oncoverity Inc.
Target Recruit Count
26
Registration Number
2024-510991-19-00
Locations
🇩🇪

Medizinische Hochschule Hannover, Hanover, Germany

🇩🇪

Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Germany

🇩🇪

Goethe University Frankfurt, Frankfurt Am Main, Germany

and more 1 locations

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Phase 1
Completed
Conditions
Leukemia, Myeloid, Acute
Interventions
First Posted Date
2020-01-27
Last Posted Date
2023-08-09
Lead Sponsor
OncoVerity, Inc.
Target Recruit Count
6
Registration Number
NCT04241549
Locations
🇯🇵

Fukushima Medical University Hospital, Fukushima, Japan

🇯🇵

Gunmaken Saiseikai Maebashi Hospital, Maebashi, Japan

🇯🇵

Osaka City General Hospital, Osaka, Japan

and more 2 locations

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Phase 1
Active, not recruiting
Conditions
Leukemia, Myeloid, Acute
Interventions
First Posted Date
2019-11-05
Last Posted Date
2025-04-17
Lead Sponsor
OncoVerity, Inc.
Target Recruit Count
61
Registration Number
NCT04150887
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Norton Cancer Institute, Louisville, Kentucky, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 20 locations

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Phase 2
Active, not recruiting
Conditions
Leukemia, Myeloid, Acute
Interventions
First Posted Date
2019-07-17
Last Posted Date
2025-02-28
Lead Sponsor
OncoVerity, Inc.
Target Recruit Count
103
Registration Number
NCT04023526
Locations
🇦🇺

St Vincents Hospital Sydney, Darlinghurst, Australia

🇦🇺

St Vincents Hospital Melbourne, Fitzroy, Australia

🇦🇺

The Alfred Hospital, Melbourne, Australia

and more 53 locations

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Phase 1
Completed
Conditions
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Interventions
First Posted Date
2017-01-25
Last Posted Date
2023-08-09
Lead Sponsor
OncoVerity, Inc.
Target Recruit Count
38
Registration Number
NCT03030612
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.